With box warnings

Without box warnings

Branded

Generic

3 results

gavreto
(Pralsetinib)
Rigel Pharmaceuticals, Inc.
Usage: GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.
rezlidhia
(olutasidenib)
Rigel Pharmaceuticals, Inc.
Usage: REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as confirmed by an FDA-approved test.
tavalisse
(FOSTAMATINIB)
Rigel Pharmaceuticals, Inc.
Usage: TAVALISSE is approved for treating thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have not adequately responded to prior treatments.

Rigel Pharmaceuticals, Inc. drugs

gavreto